NXI Therapeutics names new CEO

30 November 2022

Venture Kick backed Swiss biotech NXI Therapeutics (formerly NextImmune) today announced the appointment of Dr Ruben Herrendorff as its new chief executive (CEO) to drive the next stage of the company’s development.

Dr Herrendorff was previously co-founder and CEO of Polyneuron Pharmaceuticals AG, a blue-chip VC-backed biotech developing a new antigen-specific technology platform to tackle antibody-mediated autoimmune diseases.

The company also announced that it has appointed Dr Ulf Grawunder to its board of directors. Dr Grawunder is a successful serial biotech entrepreneur, who has founded and exited two biotech companies since 2004: 4-Antibody (sold to US-based Agenus) and NBE-Therapeutics (sold to Boehringer Ingelheim). Recently, he became managing partner at Swiss Viopas Venture Consulting and he has co-founded T-CURX, which is focused on the development of next-generation CAR-T cell therapies for cancer patients, where he has recently assumed the position of CEO.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK